# Harry Glorikian

> Harry Glorikian is a Series A investor at Scientia Ventures backing Artificial Intelligence. See 3 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Scientia Ventures](https://shizune.co/investors/profile/scientia-ventures)
- Total investments: 3
- Last investment: Apr 2025
- Lead investor: 33%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/harryglorikian

Harry Glorikian is a Series A investor at Scientia Ventures focused on Artificial Intelligence and SaaS. Harry Glorikian is the General Partner at Scientia Ventures.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Artificial Intelligence | 2 | 67% |
| SaaS | 1 | 33% |
| Content | 1 | 33% |
| Medical | 1 | 33% |
| Analytics | 1 | 33% |

16 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 2 | 67% |
| Angel | 1 | 33% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 2 | 67% |
| United Kingdom | 1 | 33% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Emerald | Emerald is a preventive health membership with local screenings, all your data in one place, and an action plan unique to your biology. | $850K | Angel | Apr 30, 2025 |  |
| MarketMuse | MarketMuse is a market-leading demand generation platform focused on AI-driven content. Our SaaS platform analyzes massive amounts of Web data to build articles that drive search traffic and engagement. Over 230 companies in enterprise software, financial services, life sciences and publishing use MarketMuse to realize 2-3X gains in productivityand 2X-8X improvements in search traffic within the first 6 months. A pioneer in the industry, MarketMuse was named the "undisputed champion of the content optimization space" by industry analysts in 2019. | $2.5M | Series A | Mar 18, 2020 |  |
| Transparency Life Sciences | Transparency Life Sciences, the first all-digital clinical development services company, harnesses crowdsourcing and mobile health technology to advance biopharma drug candidates through clinical trials with unprecedented patient relevance and efficiency.The TLS model is highly scalable and is designed to increase current industry margins of awasteful process that often collects irrelevant data. Drug companies will outsource an estimated $38B of clinical trial services to CROs by 2020, with a CAGR of 9-10%. Yet this robust growth masks significant customer dissatisfaction. Sponsors want clinical trials to be better-designed, technologically advanced, patient-centric, and significantly less expensive, yet change has been limited by an inability to see beyond the current outmoded, site-centric model.As a consequence, only select compounds are being developed in humans, leaving many potential important therapies untested in clinical trials. Rapid advances in digital technology and strong regulatory support create a historic opportunity for TLS to catalyze a fundamental transformation, significantly improving the quality of clinical trials while reducing their cost. | $5M | Series A | Feb 15, 2018 |  |

3 of 3 investments shown.

## Co-investors
- [Crowdcube](https://shizune.co/investors/profile/crowdcube) — VC Fund, 1 deal together
- [Informa Ventures](https://shizune.co/investors/profile/informa-ventures) — VC Fund, 1 deal together
- [Riverside Company](https://shizune.co/investors/profile/riverside) — VC Fund, 1 deal together
- [SmartHub](https://shizune.co/investors/profile/smarthub-2) — VC Fund, 1 deal together
- [Upscalers](https://shizune.co/investors/profile/upscalers-investment-club) — VC Fund, 1 deal together
- [Zelkova Ventures](https://shizune.co/investors/profile/zelkova-ventures) — VC Fund, 1 deal together

## About Scientia Ventures

VC Fund · New York, United States

Scientia Ventures invests in early to mid-stage technology companies that target computational biology and chemistry, the digitization of medicine, and digital therapies as well as traditional drug development companies at the cutting edge of the life sciences.

1 contacts available at Scientia Ventures.

| Name | Title | Profile |
| --- | --- | --- |
| Harry Glorikian | General Partner | https://shizune.co/investors/profile/harry-glorikian-2470 |

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [Qiming Venture Partners](https://shizune.co/investors/profile/qiming-venture-partners) — VC Fund
- [Bpifrance](https://shizune.co/investors/profile/bpifrance) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

### Similar country
- [SFC Capital](https://shizune.co/investors/profile/startup-funding-club) — VC Fund
- [Fuel Ventures](https://shizune.co/investors/profile/fuel-ventures-fund) — VC Fund
- [Business Growth Fund](https://shizune.co/investors/profile/business-growth-fund) — VC Fund

## Featured in investor lists
- [Medical Angel Investors in United Kingdom](https://shizune.co/investors/medical-angel-investors-united-kingdom)

## FAQ

### What does Harry Glorikian invest in?

Harry Glorikian invests primarily in Artificial Intelligence, SaaS and Content startups, most often at Series A and Angel stage. Most of the 3 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Harry Glorikian last invest?

The most recent investment recorded for Harry Glorikian closed in Apr 2025. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co